Show simple item record

dc.contributor.authorSimos, D
dc.contributor.authorSajjady, G
dc.contributor.authorSergi, M
dc.contributor.authorLiew, M
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorHo, C
dc.contributor.authorLeighl, N
dc.contributor.authorWhite, S
dc.contributor.authorSummers, Yvonne J
dc.contributor.authorPetrcich, W
dc.contributor.authorWheatley-Price, P
dc.date.accessioned2014-02-10T11:20:28Z
dc.date.available2014-02-10T11:20:28Z
dc.date.issued2013-11-14
dc.identifier.citationThird-line chemotherapy in small-cell lung cancer: an international analysis. 2013: Clin Lung Canceren
dc.identifier.issn1938-0690
dc.identifier.pmid24365050
dc.identifier.doi10.1016/j.cllc.2013.11.003
dc.identifier.urihttp://hdl.handle.net/10541/312410
dc.description.abstractSmall-cell lung cancer is an aggressive disease for which the mainstay of treatment is chemotherapy. Despite good initial responses most patients will relapse. Some will receive second-line therapy with clinical benefit, but for third-line chemotherapy there is little evidence to guide treatment decisions and the benefits of treatment are unknown. This study investigated the treatment of SCLC in the third-line setting.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Clinical lung canceren
dc.titleThird-line chemotherapy in small-cell lung cancer: an international analysis.en
dc.typeArticleen
dc.identifier.journalClinical Lung Canceren
html.description.abstractSmall-cell lung cancer is an aggressive disease for which the mainstay of treatment is chemotherapy. Despite good initial responses most patients will relapse. Some will receive second-line therapy with clinical benefit, but for third-line chemotherapy there is little evidence to guide treatment decisions and the benefits of treatment are unknown. This study investigated the treatment of SCLC in the third-line setting.


Files in this item

This item appears in the following Collection(s)

Show simple item record